Eli Lilly Stock Hits Record High Amid Obesity Drug Deal, Earnings Surge, and Analyst Upgrades

Eli Lilly's stock has surged to record levels after striking a deal with the US government to expand access to its obesity medicines, delivering impressive Q3 results fueled by high demand for weight-loss drugs. The company's valuation is now above $1,025, with some analysts considering it undervalued given its future prospects. However, supply constraints and potential side effects could impact growth and pressure valuations.